StreetInsider.com News Articles

ProQR Therapeutics N.V. (PRQR) PT Lowered to $8 at H.C. Wainwright

Thu, 01 Oct 2026 06:58:28 -0400

(Updated - October 1, 2026 6:58 AM EDT)

H.C. Wainwright analyst Andrew Fein lowered the price target on ProQR Therapeutics N.V. (NASDAQ: PRQR) to $8.00 (from $12.00) while maintaining a Buy rating.

The analyst commented: "Yesterday, ProQR hosted an R&D day focused on NTCP modulation in biliary atresia (BA), led by Prof. Gideon Hirschfield of the Toronto Centre for Liver Disease. Given the initial AX-0810 data, clean safety with no SAEs, no pruritus and no bilirubin change (supporting no OATP off-target), concordant dose-dependent engagement across all three predefined biomarkers, and an 8-week half-life, together with the human genetic support from NTCP-deficient individuals

ProQR Therapeutics N.V. (PRQR) PT Lowered to $8 at H.C. Wainwright

Thu, 01 Oct 2026 06:58:28 -0400

(Updated - October 1, 2026 6:58 AM EDT)

H.C. Wainwright analyst Andrew Fein lowered the price target on ProQR Therapeutics N.V. (NASDAQ: PRQR) to $8.00 (from $12.00) while maintaining a Buy rating.

ProQR Therapeutics N.V. (PRQR) Reiterated at Market Outperform by Citizens Ahead of Ph1 Readouts

Thu, 01 Oct 2026 04:14:20 -0400

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $8.00 price target on ProQR Therapeutics N.V. (NASDAQ: PRQR).

The analyst commented, "ProQR hosted an Investor Event featuring pediatric hepatologist Dr. Gideon Hirschfield to discuss the potential of NTCP modulation in biliary atresia (BA) ahead of near-term Phase 1 readouts for AX-0810 and AX-0811; we reiterate our Market Outperform rating and $8 price target based on a sum-of-the-parts analysis. Dr. Hirschfield discussed the unmet need in BA, the rationale for NTCP modulation, and his expectations for subsequent clinical benefit. PRQR will have additional data for AX-0810 by YE and first-in-human data

ProQR names new AI chief and adds Hugging Face co-founder to board

Wed, 23 Sep 2026 08:00:15 -0400

ProQR Therapeutics N.V. (Nasdaq: PRQR) announced the appointment of Chris Hart, PhD, as Chief Data and AI Officer and Thomas Wolf, PhD, as a strategic AI advisor to its board of directors, the company said in a statement dated Sept. 23, 2026.

Hart most recently served as Vice President of Data Science and AI/ML in the Genetic Medicines team at Eli Lilly and Company. He previously founded Creyon Bio and spent seven years at Ionis Pharmaceuticals, where he led the company's functional genomics group. He holds a PhD from the California Institute of Technology and completed postdoctoral training at Yale University.

Wolf

Form 6-K ProQR Therapeutics N.V. For: Sep 23

Wed, 23 Sep 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260923/27093536.html

ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor

Wed, 23 Sep 2026 08:00:00 -0400

Appointments support ProQR’s strategy to scale AI across the discovery and development of medicines using its Axiomer RNA editing platform and pipeline
AX-0811, the first ProQR program identified through its AI-enabled discovered engine in clinical testing, with target engagement data expected in early January 2027
ProQR’s expanded AI strategy is directly supporting the ongoing development programs; the Company expects up to 5 clinical data readouts over the next 12 months across 4 development programs

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 23, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company

ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor

Wed, 23 Sep 2026 08:00:00 -0400

Appointments support ProQR’s strategy to scale AI across the discovery and development of medicines using its Axiomer RNA editing platform and pipeline
AX-0811, the first ProQR program identified through its AI-enabled discovered engine in clinical testing, with target engagement data expected in early January 2027
ProQR’s expanded AI strategy is directly supporting the ongoing development programs; the Company expects up to 5 clinical data readouts over the next 12 months across 4 development programs

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 23, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company

ProQR doses first participant in Phase 1 trial of AX-0811

Wed, 09 Sep 2026 08:00:22 -0400

ProQR Therapeutics N.V. (Nasdaq: PRQR) announced that the first participant has been dosed in a Phase 1 clinical trial of AX-0811 in healthy volunteers, according to a company statement dated Sept. 9, 2026.

AX-0811 is an investigational RNA editing oligonucleotide developed to modulate NTCP, a protein involved in bile acid transport. The company says preclinical data show greater potency and a longer half-life for AX-0811 compared with its predecessor, AX-0810. ProQR is developing the therapy as a potential treatment for cholestatic liver diseases, including biliary atresia.

The Phase 1 study is designed to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamic biomarkers in healthy

ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026

Wed, 09 Sep 2026 08:00:00 -0400

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that the first participant has been dosed in the Phase 1 clinical trial of AX-0811 in healthy volunteers.

AX-0811 is ProQR’s next-generation, AI-discovered investigational RNA editing oligonucleotide (EON) designed to modulate NTCP, with preclinical data demonstrating greater potency and a longer half-life compared with AX-0810. AX-0811 is being developed as a potential disease-modifying treatment for cholestatic

ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026

Wed, 09 Sep 2026 08:00:00 -0400

ProQR to Participate in Upcoming Investor Conferences in September 2026

Wed, 02 Sep 2026 08:00:00 -0400

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that company management will participate in the following upcoming investor conferences:

Wells Fargo 21^st Annual Healthcare Conference – Boston, MA
1x1s on Tuesday, September 8
2026 Cantor Global Healthcare Conference – New York, NY
Fireside chat at 11:30am ET and 1x1s on Wednesday, September 9

Additional details, including webcast information where applicable, will be

ProQR to Participate in Upcoming Investor Conferences in September 2026

Wed, 02 Sep 2026 08:00:00 -0400

Wells Fargo 21^st Annual Healthcare Conference – Boston, MA
1x1s on Tuesday, September 8
2026 Cantor Global Healthcare Conference – New York, NY
Fireside chat at 11:30am ET and 1x1s on Wednesday, September 9

Additional details, including webcast information where applicable, will be

BofA Securities Starts ProQR Therapeutics N.V. (PRQR) at Buy

Thu, 20 Aug 2026 07:15:47 -0400

(Updated - August 20, 2026 7:15 AM EDT)

BofA Securities analyst Alec Stranahan initiates coverage on ProQR Therapeutics N.V. (NASDAQ: PRQR) with a Buy rating and a price target of $8.00.

The analyst comments "We initiate coverage of ProQR with a Buy rating and $8 PO. AX-0810 (NTCP, the liver’s bile acid transporter) provides the first human validation of Axiomer, ProQR’s technology for making precise, temporary RNA changes. ProQR initially targets biliary atresia, a childhood disease where damaged bile ducts can lead to liver failure, affecting roughly 20k patients globally with no approved disease-modifying therapy. ‘0810 and nextgeneration ‘0811 aim to reduce

BofA Securities Starts ProQR Therapeutics N.V. (PRQR) at Buy

Thu, 20 Aug 2026 07:15:47 -0400

(Updated - August 20, 2026 7:15 AM EDT)

BofA Securities analyst Alec Stranahan initiates coverage on ProQR Therapeutics N.V. (NASDAQ: PRQR) with a Buy rating and a price target of $8.00.

H.C. Wainwright Reiterates Buy Rating on ProQR Therapeutics N.V. (PRQR)

Mon, 17 Aug 2026 06:52:52 -0400

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $12.00 price target on ProQR Therapeutics N.V. (NASDAQ: PRQR).

The analyst commented: "We continue to focus on AX-0810 as one of the key value drivers for ProQR. The target engagement data which showed up to 8-fold dose-dependent serum bile acid elevation, concordant conjugated bile acid and TUDCA shifts, no serious adverse events or pruritus, and an eight-week half-life (based on interim data) supporting infrequent dosing, remains the first clinical validation of the Axiomer platform and supports advancement into patient study, in our opinion. With respect to '0810, we note that Ipsen

Form 6-K ProQR Therapeutics N.V. For: Jun 30

Thu, 13 Aug 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260813/26916240.html

Form 6-K ProQR Therapeutics N.V. For: Jun 30

Thu, 13 Aug 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260813/26916240.html

Form 6-K ProQR Therapeutics N.V. For: Aug 13

Thu, 13 Aug 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260813/26916214.html

Form 6-K ProQR Therapeutics N.V. For: Aug 13

Thu, 13 Aug 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260813/26916214.html

ProQR Announces Second Quarter 2026 Operating and Financial Results

Thu, 13 Aug 2026 07:00:00 -0400

First clinical validation of Axiomer™ RNA editing established through NTCP modulation with positive AX-0810 clinical target engagement data; full Phase 1 dataset to be presented at a medical or scientific conference later this year
Multiple clinical milestones, including initial AX-0811 Phase 1 data expected by year-end 2026, followed in H1 2027 by:
- biliary atresia IIT initiation and initial data,
- initial AX-0422 (IDUA) patient data in MPS I Hurler syndrome, and
- advancement of AX-2911 (PNPLA3) to the clinic
Strengthened balance sheet through $59.2 million financing during the quarter; ended Q2 2026 with € 117.1

ProQR Announces Second Quarter 2026 Operating and Financial Results

Thu, 13 Aug 2026 07:00:00 -0400

First clinical validation of Axiomer™ RNA editing established through NTCP modulation with positive AX-0810 clinical target engagement data; full Phase 1 dataset to be presented at a medical or scientific conference later this year
Multiple clinical milestones, including initial AX-0811 Phase 1 data expected by year-end 2026, followed in H1 2027 by:
- biliary atresia IIT initiation and initial data,
- initial AX-0422 (IDUA) patient data in MPS I Hurler syndrome, and
- advancement of AX-2911 (PNPLA3) to the clinic
Strengthened balance sheet through $59.2 million financing during the quarter; ended Q2 2026 with € 117.1

Form 4 ProQR Therapeutics N.V. For: Jul 31 Filed by: de Boer Daniel Anton

Mon, 03 Aug 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260803/26857540.html

Form 4 ProQR Therapeutics N.V. For: Jul 31 Filed by: de Boer Daniel Anton

Mon, 03 Aug 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260803/26857540.html

Form SCHEDULE 13D/A ProQR Therapeutics N.V. Filed by: VAN HERK INVESTMENTS B.V.

Wed, 29 Jul 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260729/26834783.html

Form SCHEDULE 13D/A ProQR Therapeutics N.V. Filed by: VAN HERK INVESTMENTS B.V.

Wed, 29 Jul 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260729/26834783.html